Preliminary mechanisms of regulating PD‑L1 expression in non‑small cell lung cancer during the EMT processFang Li, Li Liang|Oncology Reports|2018Cited by 32
Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational studyHongge Liang, Mengzhao Wang, Liangming Zhang et al.|Thoracic Cancer|2019Cited by 26
Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in ChinaPuyuan Xing, Junling Li, Shouzheng Wang et al.|Targeted Oncology|2019Cited by 14
Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort studyPuyuan Xing, Junling Li, Di Ma et al.|Chinese Journal of Cancer Research|2019Cited by 9
Clinical features and outcomes of<i>ALK</i>rearranged non‐small cell lung cancer with primary resistance to crizotinibDi Ma, Junling Li, Yan Zhang et al.|Thoracic Cancer|2019Cited by 6